Skip to main content

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

Written by Customer Service on . Posted in Public Companies.

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management

ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA.

“ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce our mission to deliver meaningful therapeutic options for diverse patient populations who need alternatives to statins.”

Moderated Presentations
 
Title:

Session:
Location:
Date & Time:
Authors:

Presenter:

Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant
Patients: An Analysis of The Clear Outcomes Trial
1069
Moderated Poster Theatre 06, Posters, Hall E
Saturday, March 28, 2026, 4:18 – 4:25 pm ET
C. Pires Zingano, D. Brennan, M. Li, W. Sasiela, L. Bloedon, S.E.
Nissen, L.J. Laffin
Carolina Pires Zingano, MD (Cleveland Clinic)
  
Title:

Session:
Location:
Date & Time:
Authors:

Presenter:

Bempedoic Acid and Cardiovascular Outcomes in Patients with Autoimmune
or Inflammatory Diseases: An Analysis of the Clear Outcomes Trial
1084
Moderated Poster Theater 05, Posters, Hall E
Sunday, March 29, 2026, 9:30 – 9:37 am ET
B. Frison Spiazzi, B. Weber, D. Brennan, L. Bloedon, M. Li, S.E. Nissen, L.J.
Laffin
Bernardo Frison Spiazzi, MD (Cleveland Clinic)
 

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.